During a poster session which will take place on 7 and 8 May 2018 at the Representatives of the American Psychiatric Association Annual Meeting CNS Research Group, representatives of the CNS Research Group will present two projects from the Company’s innovative portfolio. The sessions will be run by Mikołaj Matłoka - Leader of the CNS Research Group at Celon Pharma S.A. Two posters will be presented: PZ-KKN-94: A Novel and Potent Antagonist of 5-HT6 Receptor With Procognitive and Antidepressant Activity in Animal Models as well as Pharmacokinetic Properties of Esketamine and Ketamine Racemate After Dry Powder Inhalation, Intravenous, and Intratracheal Administration in Rats.
Both projects to be presented are being developed in the area of neuropsychiatric diseases. Their potential application can include treatment of drug-resistant depression or behavioural disorders. They could potentially also be covered by a global commercialisation strategy which the Company is planning in cooperation with Plexus Ventures.